Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

2,182 resultsPage 91 of 182, newest first
  1. HealthcareBlue Shield of CaliforniaBLUE SHIELD OF CALIFORNIA EXPANDS VIRTUAL BLUE PROGRAM, BRINGING $0 OUT-OF-POCKET VIRTUAL CARE BENEFIT TO 260,000 MORE MEMBERSExpansion will more than double program enrollment; members get unlimited virtual primary, behavioral health, and specialist visits with $0 out-of-pocket costs and often same-day access. — Blue Shield of California today announced a...
  2. HealthcareAlice L. Walton FoundationAlice L. Walton Foundation and Mercy Break Ground on AWSOM Whole Health Campus, Marking a New Era for Whole-Person Health in the HeartlandBuildings for world-class specialty care, including cardiac and cancer care, will anchor the first phase of a 120+-acre destination Key Points The Alice L. Walton Foundation and Mercy broke ground on a 120+-acre campus for specialty care and whole-health innovation in Bentonville,...
  3. FinanceBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruger & Company, Inc. (NYSE – RGR), Atkore, Inc. (NYSE – ATKR), Centerspace (NYSE – CSR), Aethlon Medical, Inc. (Nasdaq – AEMD)Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
  4. FinanceFaruqi & Faruqi LLPFaruqi & Faruqi, LLP Urges Hims & Hers Health, Inc. (HIMS) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class ActionFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Hims to Contact Him Directly to Discuss Their OptionsNew York, New York--(September 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:...
  5. HealthcareBetterLife Pharma Inc.BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsBetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together with the Common Shares, the...
  6. HealthcareNational Comprehensive Cancer NetworkThere's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient ResourceNew guideline for patients and caregivers explains the importance of assessments to tailor cancer care to every person, regardless of age. — Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer...
  7. HealthcareShane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging PharmaChief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma
  8. HealthcareThe Phia Group, LLCEmployers May Be Asking the Wrong Questions About Their Health Plans, New Survey FindsThe 2026 Phia Group Broker Survey of 124 brokers and advisors finds a disconnect between employer health plan questions and broker concerns about fiduciary processes, plan-performance visibility and vendor oversight. CANTON, Mass., Sept. 17, 2026 -- Employers are entering the...
  9. HealthcareAdaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey
  10. HealthcareMatisse Pharmaceuticals closed Series A financing round to advance isupartob sodium through phase 2 clinical developmentMatisse Pharmaceuticals B.V., developing isupartob sodium for the treatment of sepsis, today announced the successful completion of a Series A round.
  11. FinanceArtiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumArtiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.
  12. SaaSAerska Appoints Laura Sepp-Lorenzino to Scientific Advisory BoardDUBLIN and LONDON, 17 September 2026 -- Aerska, a biotechnology company bringing RNA medicines to the brain through its antibody-oligonucleotide conjugate (AOC) platform, today announces the appointment of Laura Sepp-Lorenzino to its Scientific Advisory Board, bringing more than 30 years of drug development leadership spanning nucleic acid therapies and gene editing, from early discovery through late-stage clinical development.